CNW/ - Springbok Analytics ( a leader in AI-powered muscle analysis, today announced its role in MOVE Peds, the first ...

An onslaught of new setbacks due to FSHD disease progression has left columnist Robin Stemple understandably anxious about ...

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic condition that affects muscle function, often making everyday tasks — like smiling or lifting one’s arms — difficult. For ...

Sheffield is one of only two non-American centres in the world recruiting patients into the trial, according to the NHS. Dr Channa Hewamadduma, principal investigator and lead neuromuscular consultant ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

The lead asset is a siRNA molecule called AOC1001. Facioscapulohumeral Muscular Dystrophy (FSHD): weakens muscles in the face, shoulders, and upper arms. The target is DUX4 (Double Homeobox 4), a ...

Distinguished new members of the FSHD Society's Board of Directors bring expertise to help accelerate treatments and expand advocacy for the FSH muscular dystrophy community. Mel Hayes ...